In AI for science, the true competitive advantage lies in generating unique, high-quality experimental data from self-driving labs. The AI models themselves are becoming commoditized, while the physical data remains the defensible asset.

Pacesa argues that closed-source models won't significantly outperform open-source tools because most rely on the same public PDB data. The true competitive advantage lies not in tweaking algorithms but in generating massive, proprietary, high-quality experimental datasets that can train genuinely superior models.

Xaira's core strategy involves creating massive, proprietary datasets that reveal causal biology. By systematically perturbing every gene in a cell to observe its effects, they generate unique training data for their models, quadrupling the world's supply of such information with a single publication.

The next inflection point will come from clever data generation strategies optimized for AI models, not human analysis. This "black box data" approach—like pooled screening with sequencing readouts—is vastly more scalable and creates a powerful, proprietary moat for companies.

The company's core strategy is "data-first," believing the true long-term differentiator in AI drug discovery is generating unique, high-quality experimental data, not just innovating on model architecture, which they see as prone to commoditization when trained on public data.

InduPro's AI advantage isn't a better algorithm but a superior, proprietary dataset generated in-house. This high-quality data, combining proximity maps with protein quantification, is the true differentiator that their tailor-made AI tools interrogate, avoiding reliance on public data.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

Algorithmic improvements alone are not enough for a new AI lab to challenge incumbents, who are also researching next-gen architectures. The only viable path is to focus on domains where proprietary data can be generated and is unavailable to the big labs, such as robotics or specialized life sciences.